Literature DB >> 2963184

Endogenous platelet-activating factor and anti-platelet-activating factor in patients with renovascular hypertension.

F Masugi1, T Ogihara, S Saeki, K Sakaguchi, Y Kumahara, K Satouchi, M Oda, K Saito, K Tokunaga.   

Abstract

Renovascular hypertension is relieved by percutaneous transluminal renal angioplasty. In four patients with renovascular hypertension, platelet-activating factor (PAF) was found to be released into the ipsilateral renal venous blood after percutaneous transluminal renal angioplasty, but was not found in the contralateral renal venous blood following this procedure. Anti-platelet-activating factor with a lipid-like property was also found, and its polarity was slightly lower than that of PAF judging by its behavior on thin layer chromatography. Anti-platelet-activating factor completely blocked the aggregation of rabbit platelets induced by PAF, ADP or arachidonic acid. These results indicate that PAF and anti-platelet-activating factor are released into renal venous blood following percutaneous transluminal renal angioplasty in patients with renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2963184     DOI: 10.1016/0024-3205(88)90084-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation.

Authors:  D Tsoukatos; C A Demopoulos; A D Tselepis; M C Moschidis; A Donos; A Evangelou; J Benveniste
Journal:  Lipids       Date:  1993-12       Impact factor: 1.880

2.  A specific, sensitive and high-capacity immunoassay for PAF.

Authors:  B A Baldo; M A Smal; A C McCaskill
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Inhibitor(s) of platelet-activating factor (PAF) in human saliva.

Authors:  M A Smal; B A Baldo
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.